- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07252739
KEYMAKER-U01 Подисследование 01J: Исследование Пембролизумаба плюс MK-1084 у участников с немелкоклеточным раком легкого (НМРЛ) с мутациями гомолога вирусного онкогена саркомы крыс Кирстен (KRAS) G12C (MK-3475-01J/KEYMAKER-U01J)
КЛИЧ-U01 Подисследование 01J: Рандомизированное исследование фазы 2 по типу «зонтичной» схемы со скользящими ветвями исследуемых препаратов для терапии первой линии у пациентов с распространенным или метастатическим неплоскоклеточным немелкоклеточным раком легкого (НМРЛ) с мутациями KRAS G12C
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Контакты исследования
- Имя: Toll Free Number
- Номер телефона: 1-888-577-8839
- Электронная почта: Trialsites@msd.com
Места учебы
-
-
-
Central, Гонконг, 0000
- Рекрутинг
- Hong Kong Integrated Oncology Centre ( Site 0232)
-
Контакт:
- Study Coordinator
- Номер телефона: +85237006888
-
Hong Kong, Гонконг
- Рекрутинг
- Queen Mary Hospital ( Site 0230)
-
Контакт:
- Study Coordinator
- Номер телефона: +85222551727
-
Kowloon, Гонконг
- Рекрутинг
- Hong Kong United Oncology Centre ( Site 0231)
-
Контакт:
- Study Coordinator
- Номер телефона: +852 2386 8002
-
-
-
-
Attica
-
Athens, Attica, Греция, 106 76
- Рекрутинг
- Evangelismos General Hospital of Athens ( Site 0200)
-
Контакт:
- Study Coordinator
- Номер телефона: +302132041631
-
-
-
-
-
Seville, Испания, 41009
- Рекрутинг
- Hospital Universitario Virgen de la Macarena ( Site 0093)
-
Контакт:
- Study Coordinator
- Номер телефона: +34 671560092
-
-
-
-
Lombardy
-
Milan, Lombardy, Италия, 20133
- Рекрутинг
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
-
Контакт:
- Study Coordinator
- Номер телефона: 00390223903829
-
-
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210000
- Рекрутинг
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
-
Контакт:
- Study Coordinator
- Номер телефона: +8602568182222
-
-
Jiangxi
-
Nanchang, Jiangxi, Китай, 330209
- Рекрутинг
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
-
Контакт:
- Study Coordinator
- Номер телефона: +86 791 8631 9333
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200032
- Рекрутинг
- Zhongshan Hospital Fudan University ( Site 0319)
-
Контакт:
- Study Coordinator
- Номер телефона: +8615000229853
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610066
- Рекрутинг
- West China Hospital, Sichuan University ( Site 0315)
-
Контакт:
- Study Coordinator
- Номер телефона: +8618980602252
-
-
-
-
Overijssel
-
Deventer, Overijssel, Нидерланды, 7416 SE
- Рекрутинг
- Deventer Ziekenhuis ( Site 0272)
-
Контакт:
- Study Coordinator
- Номер телефона: +31570536437
-
-
South Holland
-
Leiden, South Holland, Нидерланды, 2333 ZA
- Рекрутинг
- Leids Universitair Medisch Centrum ( Site 0273)
-
Контакт:
- Study Coordinator
- Номер телефона: +31715566376
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Польша, 02-781
- Рекрутинг
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
-
Контакт:
- Study Coordinator
- Номер телефона: 48 22 546 23 36
-
-
-
-
Florida
-
Clermont, Florida, Соединенные Штаты, 34711
- Рекрутинг
- Clermont Oncology Center ( Site 0041)
-
Контакт:
- Study Coordinator
- Номер телефона: 386-538-3169
-
-
North Dakota
-
Fargo, North Dakota, Соединенные Штаты, 58102
- Рекрутинг
- Sanford Health Roger Maris Cancer Center ( Site 0039)
-
Контакт:
- Study Coordinator
- Номер телефона: 701-234-2000
-
-
South Dakota
-
Sioux Falls, South Dakota, Соединенные Штаты, 57104
- Рекрутинг
- Sanford Cancer Center Oncology Clinic ( Site 0038)
-
Контакт:
- Study Coordinator
- Номер телефона: 605-328-8000
-
-
-
-
Bangkok
-
Bangkok, Bangkok, Таиланд, 10300
- Рекрутинг
- Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
-
Контакт:
- Study Coordinator
- Номер телефона: +6622443461
-
Bangkok, Bangkok, Таиланд, 10700
- Рекрутинг
- Faculty of Medicine Siriraj Hospital ( Site 0350)
-
Контакт:
- Study Coordinator
- Номер телефона: +6624194488-9
-
-
-
-
-
Adana, Турция (Туркие), 34010
- Рекрутинг
- Koç Üniversitesi Hastanesi ( Site 0142)
-
Контакт:
- Study Coordinator
- Номер телефона: 08502508250-21251
-
Adana, Турция (Туркие), 1250
- Рекрутинг
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
-
Контакт:
- Study Coordinator
- Номер телефона: +905537766235
-
Ankara, Турция (Туркие), 6230
- Рекрутинг
- Hacettepe Universite Hastaneleri ( Site 0140)
-
Контакт:
- Study Coordinator
- Номер телефона: +90 312 305 50 00
-
Ankara, Турция (Туркие), 06680
- Рекрутинг
- Liv Hospital Ankara ( Site 0146)
-
Контакт:
- Study Coordinator
- Номер телефона: 905469299990
-
-
Kayseri
-
Talas, Kayseri, Турция (Туркие), 38039
- Рекрутинг
- Erciyes University ( Site 0145)
-
Контакт:
- Study Coordinator
- Номер телефона: 905366550924
-
-
-
-
-
Kyiv, Украина, 03022
- Активный, не рекрутирующий
- VISION PARTNER Medical Centre ( Site 0135)
-
Kyiv, Украина, 03151
- Рекрутинг
- LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
-
Контакт:
- Study Coordinator
- Номер телефона: +380671502987
-
-
Cherkasy Oblast
-
Cherkasy, Cherkasy Oblast, Украина, 18009
- Рекрутинг
- COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
-
Контакт:
- Study Coordinator
- Номер телефона: +380472370123
-
-
Dnipropetrovsk Oblast
-
Kryvyi Rih, Dnipropetrovsk Oblast, Украина, 50000
- Рекрутинг
- Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
-
Контакт:
- Study Coordinator
- Номер телефона: +380677490687
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Украина, 76018
- Рекрутинг
- Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
-
Контакт:
- Study Coordinator
- Номер телефона: 380978411455
-
-
Kirovohrad Oblast
-
Kropyvnytskyi, Kirovohrad Oblast, Украина, 25011
- Рекрутинг
- Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
-
Контакт:
- Study Coordinator
- Номер телефона: +380958718674
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Украина, 79059
- Рекрутинг
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
-
Контакт:
- Study Coordinator
- Номер телефона: +380677724757
-
-
Vinnytsia Oblast
-
Vinnitsya, Vinnytsia Oblast, Украина, 21029
- Рекрутинг
- Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
-
Контакт:
- Study Coordinator
- Номер телефона: 380953105783
-
-
Zakarpattia Oblast
-
Uzhhorod, Zakarpattia Oblast, Украина, 88000
- Рекрутинг
- Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
-
Контакт:
- Study Coordinator
- Номер телефона: +380506847086
-
-
-
-
Northern Savonia
-
Kuopio, Northern Savonia, Финляндия, 70200
- Рекрутинг
- Kuopion Yliopistollinen Sairaala ( Site 0261)
-
Контакт:
- Study Coordinator
- Номер телефона: +35817173311
-
-
Pohjanmaa
-
Vaasa, Pohjanmaa, Финляндия, 65130
- Рекрутинг
- Vaasan Keskussairaala ( Site 0263)
-
Контакт:
- Study Coordinator
- Номер телефона: +358405533545
-
-
Southwest Finland
-
Turku, Southwest Finland, Финляндия, 20520
- Рекрутинг
- Turku University Hospital ( Site 0262)
-
Контакт:
- Study Coordinator
- Номер телефона: +35823138709
-
-
Uusimaa
-
Helsinki, Uusimaa, Финляндия, 00290
- Рекрутинг
- HYKS Syöpätautien klinikka ( Site 0260)
-
Контакт:
- Study Coordinator
- Номер телефона: +358406682951
-
-
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Чили, 7560908
- Рекрутинг
- Centro de Oncología de Precisión ( Site 0160)
-
Контакт:
- Study Coordinator
- Номер телефона: +56991612199
-
Santiago, Region M. de Santiago, Чили, 7500921
- Рекрутинг
- Fundacion Arturo Lopez Perez ( Site 0167)
-
Контакт:
- Study Coordinator
- Номер телефона: 56224205098
-
Santiago, Region M. de Santiago, Чили, 8420383
- Рекрутинг
- Bradfordhill ( Site 0168)
-
Контакт:
- Study Coordinator
- Номер телефона: +56998744662
-
-
-
-
-
Seoul, Южная Корея, 03722
- Рекрутинг
- Severance Hospital Yonsei University Health System ( Site 0080)
-
Контакт:
- Study Coordinator
- Номер телефона: +82222280880
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
- Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
- Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
- Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected
- Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
- Has undetectable hepatitis C (HCV) viral load if HCV-infected
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
- Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
- Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
- Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
- Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
- Has received previous treatment with an agent targeting KRAS
- Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
- Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
- Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
- Has a history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Arm A- Pembrolizumab + MK-1084
Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen. |
Oral Administration Intravenous administration
Другие имена:
|
|
Экспериментальный: Arm B- Pembrolizumab + MK-1084 + Cetuximab
Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m^2 every 2 weeks. |
Intravenous administration Oral Administration Intravenous administration
Другие имена:
|
|
Экспериментальный: Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)
Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks. |
Oral Administration Intravenous administration
Другие имена:
Injection powder for intravenous infusion
Другие имена:
Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 [Hl] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Participants with a Dose Limiting Toxicity (DLT)
Временное ограничение: Up to approximately 21 days
|
A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug. |
Up to approximately 21 days
|
|
Percentage of Participants who Experience at Least One Adverse Event (AE)
Временное ограничение: Up to approximately 84 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 84 months
|
|
Percentage of Participants who Discontinue Study Intervention Due to an AE
Временное ограничение: Up to approximately 84 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 84 months
|
|
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
Временное ограничение: Up to approximately 84 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to approximately 84 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
Временное ограничение: Up to approximately 84 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. |
Up to approximately 84 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR
Временное ограничение: Up to approximately 84 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 84 months
|
|
Overall Survival (OS)
Временное ограничение: Up to approximately 84 months
|
OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented. |
Up to approximately 84 months
|
|
Area Under the Concentration-Time Curve (AUC) for MK-1084
Временное ограничение: At designated timepoints (up to approximately 44 days)
|
Blood samples will be collected to determine the AUC of MK-1084. |
At designated timepoints (up to approximately 44 days)
|
|
Maximum Concentration (Cmax) of MK-1084
Временное ограничение: At designated timepoints (up to approximately 44 days)
|
Blood samples will be collected to estimate Cmax of MK-1084. |
At designated timepoints (up to approximately 44 days)
|
|
Trough Concentration (Ctrough) of MK-1084
Временное ограничение: At designated timepoints (up to approximately 84 months)
|
Blood samples will be collected to determine the Ctrough of MK-1084. |
At designated timepoints (up to approximately 84 months)
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 3475-01J
- U1111-1321-3999 (Идентификатор реестра: UTN)
- 2025-521939-36-00 (Идентификатор реестра: EU CT)
- 2025 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .